- Home
- ARVN vs AVK Comparison
ARVN vs AVK Comparison
Compare ARVN & AVK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- AVK
- Stock Information
- Founded
- ARVN 2015
- AVK 2003
- Country
- ARVN United States
- AVK United States
- Employees
- ARVN N/A
- AVK N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- AVK Trusts Except Educational Religious and Charitable
- Sector
- ARVN Health Care
- AVK Finance
- Exchange
- ARVN Nasdaq
- AVK Nasdaq
- Market Cap
- ARVN 438.1M
- AVK 475.9M
- IPO Year
- ARVN 2018
- AVK N/A
- Fundamental
- Price
- ARVN $9.12
- AVK $10.92
- Analyst Decision
- ARVN Buy
- AVK
- Analyst Count
- ARVN 15
- AVK 0
- Target Price
- ARVN $31.86
- AVK N/A
- AVG Volume (30 Days)
- ARVN 2.8M
- AVK 112.9K
- Earning Date
- ARVN 05-06-2025
- AVK 01-01-0001
- Dividend Yield
- ARVN N/A
- AVK 11.85%
- EPS Growth
- ARVN N/A
- AVK N/A
- EPS
- ARVN N/A
- AVK N/A
- Revenue
- ARVN $263,399,999.00
- AVK N/A
- Revenue This Year
- ARVN N/A
- AVK N/A
- Revenue Next Year
- ARVN N/A
- AVK N/A
- P/E Ratio
- ARVN N/A
- AVK N/A
- Revenue Growth
- ARVN 235.54
- AVK N/A
- 52 Week Low
- ARVN $5.94
- AVK $9.24
- 52 Week High
- ARVN $37.38
- AVK $12.16
- Technical
- Relative Strength Index (RSI)
- ARVN 52.04
- AVK 47.28
- Support Level
- ARVN $5.94
- AVK $10.56
- Resistance Level
- ARVN $6.86
- AVK $11.10
- Average True Range (ATR)
- ARVN 0.55
- AVK 0.34
- MACD
- ARVN 0.58
- AVK 0.03
- Stochastic Oscillator
- ARVN 93.47
- AVK 75.03
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.